Antigen arrays for treatment of allergic eosinophilic diseases

an array and antibody technology, applied in the field of molecular biology, virology, immunology and medicine, can solve the problems of asthmatic patients refractory to the use of corticosteroids, high cost of monoclonal antibodies, and patient compliance, and achieve the effect of inhibiting eosinophilia and inducing high titers

Inactive Publication Date: 2007-04-26
CYTOS BIOTECHNOLOGY AG
View PDF40 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0023] We have now found that a protein or peptide of IL-5, IL-13 or eotaxin bound to a core particle having a structure with an inherent repetitive organization, and hereby in particular to virus-like-particles (VLP's) and subunits of VLP's, respectively, leading to highly ordered and repetitive conjugates represent potent immunogens for the induction of antibodies specific for IL-5, IL-13 or eotaxin. Furthermore these auto-reactive antibodies inhibit eosinophilia in a mouse model of asthma. Therefore, the present invention provides a therapeutic mean for the treatment of allergic eosinophilic disease, which is based on an ordered and repetitive protein or peptide of IL-5, IL-13 or eotaxin-core particle array, and in particular a VLP- protein or peptide of IL-5, IL-13 or eotaxin-conjugate and -array, respectively. This therapeutic is able to induce high titers of anti-IL-5, IL-13 or eotaxin antibodies in a vaccinated animal and inhibit eosinophilia in a mouse model of asthma.
[0025] More specifically, the invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and hereby in particular protein or peptide of IL-5, IL-13 or eotaxin-VLP conjugates. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein or peptide of IL-5, IL-13 or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
[0041] The compositions of the present invention may be administered by various methods known in the art, but will normally be administered by injection, infusion, inhalation, oral administration, or other suitable physical methods. The compositions may alternatively be administered intramuscularly, intravenously, or subcutaneously. Components of compositions for administration include sterile aqueous (e.g., physiological saline) or non-aqueous solutions and suspensions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption.

Problems solved by technology

However they function by inducing a general immunosuppressive effect and there are adverse side effects associated with their long term use including high blood pressure, osteoporosis and development of cataracts.
Corticosteroids must be taken everyday and hence patient compliance is another issue in the successful use of these medicines.
Furthermore there are asthmatic patients refractory to the use of corticosteroids necessitating the use of alternative therapies.
Monoclonal antibodies are expensive therapeutic agents which must be taken monthly or bimonthly.
The issue of patient non-compliance resulting form repeated medical visits for administration of the injected drug is an important problem.
Furthermore, allotype variation between the patient and therapeutic antibody may lead to the monoclonal antibody therapy eventually becoming ineffective.
The high dose of mAb and the possibility of immune complex formation may also reduce the efficacy of passive immunisation.
As indicated, however, the immune system usually fails to produce antibodies against self-derived structures.
Under these conditions, coupling the self-antigen to a carrier that can deliver T help may break tolerance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen arrays for treatment of allergic eosinophilic diseases
  • Antigen arrays for treatment of allergic eosinophilic diseases
  • Antigen arrays for treatment of allergic eosinophilic diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction and Expression of Mutant Qβ Coat Proteins, and Purification of Mutant Qβ Coat Protein VLPs or Capsids

Plasmid Construction and Cloning of Mutant Coat Proteins

Construction of pQβ-240:

[0272] The plasmid pQβ10 (Kozlovska, T M, et al., Gene 137:133-137) was used as an initial plasmid for the construction of pQβ-240. The mutation Lys13→Arg was created by inverse PCR. The inverse primers were designed in inverted tail-to-tail directions:

(SEQ ID NO:356)5′-GGTAACATCGGTCGAGATGGAAAACAAACTCTGGTCC-3′and(SEQ ID NO:357)5′-GGACCAGAGTTTGTTTTCCATCTCGACCGATGTTACC-3′.

[0273] The products of the first PCR were used as templates for the second PCR reaction, in which an upstream primer

5′-AGCTCGCCCGGGGATCCTCTAG-3′(SEQ ID NO:358)

[0274] and a downstream primer

(SEQ ID NO:359)5′-CGATGCATTTCATCCTTAGTTATCAATACGCTGGGTTCAG-3′

were used. The product of the second PCR was digested with XbaI and Mph1103I and cloned into the pQβ10 expression vector, which was cleaved by the same restriction enzym...

example 2

Insertion of a Peptide Containing a Lysine Residue into the C / e1 Epitope of HBcAg(1-149).

[0310] The c / e1 epitope (residues 72 to 88) of HBcAg is located in the tip region on the surface of the Hepatitis B virus capsid (HBcAg). A part of this region (Proline 79 and Alanine 80) was genetically replaced by the peptide Gly-Gly-Lys-Gly-Gly (SEQ ID NO: 387) (HBcAg-Lys construct). The introduced Lysine residue contains a reactive amino group in its side chain that can be used for intermolecular chemical crosslinking of HBcAg particles with any antigen containing a free cysteine group.

[0311] HBcAg-Lys DNA, having the amino acid sequence shown in SEQ ID NO:78, was generated by PCRs: The two fragments encoding HBcAg fragments (amino acid residues 1 to 78 and 81 to 149) were amplified separately by PCR. The primers used for these PCRs also introduced a DNA sequence encoding the Gly-Gly-Lys-Gly-Gly peptide (SEQ ID NO: 387). The HBcAg (1 to 78) fragment was amplified from pEco63 using primers ...

example 3

Expression and Purification of HBcAg-Lys

[0314]E. coli strains K802 or JM109 were transformed with pKK-HBcAg-Lys. 1 ml of an overnight culture of bacteria was used to innoculate 100 ml of LB medium containing 100 μg / ml ampicillin. This culture was grown for 4 hours at 37° C. until an OD at 600 nm of approximately 0.8 was reached. Induction of the synthesis of HBcAg-Lys was performed by addition of IPTG to a final concentration of 1 mM. After induction, bacteria were further shaken at 37° C. for 4 hours. Bacteria were harvested by centrifugation at 5000 x g for 15 minutes. The pellet was frozen at -80° C. The pellet was thawed and resuspended in bacteria lysis buffer (10 mM Na2HPO4, pH 7.0, 30 mM NaCl, 0.25% Tween-20, 10 mM EDTA) supplemented with 200 μg / ml lysozyme and 10 μl of Benzonase (Merck). Cells were incubated for 30 minutes at room temperature and disrupted by sonication. E. coli cells harboring pKK-HBcAg-Lys expression plasmid or a control plasmid were used for induction of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular massaaaaaaaaaa
massaaaaaaaaaa
molecular massaaaaaaaaaa
Login to view more

Abstract

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and / or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] The present application is a continuation of U.S. application Ser. No. 10 / 289,454, filed Nov. 7, 2002, now allowed, which claims the benefit of the filing dates of U.S. Provisional Appl. Nos. 60 / 331,045, filed Nov. 7, 2001, and 60 / 396,636, filed Jul. 19, 2002. U.S. application Ser. No. 10 / 289,454 is also a continuation-in-part of, and claims priority to, U.S. application Ser. No. 10 / 050,902, filed Jan. 18, 2002, and International Appl. No. PCT / IB02 / 00166, filed Jan. 21, 2002, the latter of which was published under PCT Article 21(2) in the English language as WO 02 / 056905 on Jul. 25, 2002, both of which applications claim the benefit of the filing dates of U.S. Provisional Application Nos. 60 / 262,379, 60 / 288,549, 60 / 326,998 and 60 / 331,045, filed Jan. 19, 2001, May 4, 2001, Oct. 5, 2001, and Nov. 7, 2001, respectively. The disclosures of all of the above-referenced applications are incorporated by reference herein in their entireties.BAC...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68A61K31/70A01N43/04C12N15/09A61K38/095A61K39/00A61K39/35A61K39/39A61K47/48A61P11/06A61P35/00A61P37/08C07K14/005C07K14/01C07K14/02C07K14/08C07K14/47C07K14/52C07K14/54C07K16/00C07K16/08C07K16/22C07K16/28C07K16/40C07K16/42C07K19/00C12N7/00C12N7/01
CPCA61K38/162A61K39/0005A61K39/0007A61K39/0008A61K39/001A61K39/35A61K39/385A61K39/39A61K47/4833A61K47/48776A61K2039/5256A61K2039/5258A61K2039/6075A61K2039/627C07K14/005C07K14/523C07K14/5409C07K14/5437C07K16/00C07K16/082C07K16/22C07K16/2863C07K16/2875C07K16/40C07K16/4291C07K2317/55C07K2319/00C07K2319/30C12N2730/10122C12N2730/10123C12N2730/10142C12N2795/18122C12N2810/852A61K38/00C07K2317/34C07K2317/52A61K47/646A61K47/6901A61P11/06A61P31/12A61P35/00A61P37/08
Inventor BACHMANN, MARTIN F.JENNINGS, GARYSONDEREGGER, IVO
Owner CYTOS BIOTECHNOLOGY AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap